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Sensitivity to Fas-mediated apoptosis is null or weak in
B-cell non-Hodgkin's lymphomas and is moderately
increased by CD40 ligation
L Xerri1 2, R Bouabdallah1, E Devilard1l2, J Hassoun1, A-M Stoppa1 and F Birg2
'Department of Hematopathology, Institut Paoli-Calmettes, Marseilles; 2INSERM U 119, Marseilles, France
Summary The Fas receptor (APO-1/CD95) is capable of inducing apoptosis of lymphoid cells and is expressed in some non-Hodgkin's
lymphomas (NHLs). Fas expression is up-regulated at the surface of normal B cells upon triggering of the CD40 receptor. In this report, we
investigated the sensitivity of NHLs to Fas-mediated apoptosis induced by anti-Fas monoclonal antibodies (MAbs) and its possible
modulation by CD40 ligation in 18 NHL biopsy samples of various histological subtypes. Flow cytometric analysis showed that the fraction of
Fas-expressing lymphoma cells was highly variable from sample to sample (from 1% to 93%, mean value 46%). The frequency of apoptotic
cells was not significantly increased upon treatment with an anti-Fas MAb compared with control MAb in the 18 NHL cases analysed. The
sensitivity of lymphoma cells to Fas-mediated apoptosis was correlated neither with the histological subtypes nor with the level of Fas
expression. Activation of neoplastic B cells by CD40 ligation resulted in significant increases in Fas expression and Fas-induced apoptosis
among the five B-NHL cases tested. The overall increase in apoptotic rates was moderate and remained lower in tumour samples than in
control CD40-activated normal tonsil B cells. Altogether, our results indicate that the sensitivity to Fas-induced apoptosis is null or weak in
NHL cells, irrespective of their histological subtype, and that it can be increased to a moderate and variable degree by CD40 ligation on
neoplastic B cells. This may be an impediment to the development of Fas-based therapies for NHLs.
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Dysregulation of programmed cell death, or apoptosis, can lead to
aberrant cell accumulation and is recognized as a possible cause of
neoplasia (Korsmeyer, 1992). The contribution of apoptosis is
crucial in the pathogenesis of some non-Hodgkin's lymphomas
(NHLs), such as follicular B-cell NHLs. In this particular NHL
type, expression of the Bcl-2 antiapoptotic protein is increased in
up to 85% ofcases, because of a rearrangement of the BCL-2 gene
(Bakhshi et al, 1985).
The possible influence ofapoptosis abnormalities on the growth
of other NHL types is still debated. One of the major pathways
regulating apoptosis in lymphoid cells appears to be mediated
by the Fas antigen (APO-l/CD95), a 45-kDa membrane protein
belonging to the tumour necrosis factor receptor (TNFR) super-
family (Itoh et al, 1991; Oehm et al, 1992; Armitage, 1994). Mice
deficient in Fas or its ligand (FasL) are known as Ipr and gld mice
respectively (Watanabe-Fukunaga et al, 1992; Lynch et al, 1994).
They develop massive lymphadenopathy, splenomegaly, B-cell
activation and autoimmunity owing to unscheduled lymphocyte
accumulation (Watanabe-Fukunaga et al, 1992; Lynch et al, 1994).
In addition, Fas has also been demonstrated to act as a tumour-
suppressor gene in some particular conditions (Peng et al, 1996).
Fas is expressed in various human lymphoproliferations (M6ller
et al, 1993; Xerri et al, 1995a), Fas-positive neoplastic cells are
sometimes sensitive to Fas-mediated apoptosis induced by anti-Fas
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monoclonal antibodies (MAbs) or by FasL (Debatin et al, 1990,
1993; Rensingh-Elh et al, 1995). Injection of anti-Fas MAb into
mice carrying lymphoma xenotransplants can induce tumour
regression (Coney et al, 1994; Durandy et al, 1997). The Fas/FasL
apoptotic pathway may also play a role in the action ofchemother-
apeutic drugs (Friesen et al, 1996; Landowski et al, 1997). Taken
together, these observations suggest that Fas may be involved in the
regulation ofin vivo lymphoma growth and that Fas triggering may
be a promising strategy for treatment ofNHLs.
Although Fas expression is observed in a variety of neoplasms,
Fas-expressing cells are not uniformly sensitive to Fas-mediated
signals. Thus, myeloma cells express high Fas levels but do not
undergo apoptosis upon treatment with agonistic anti-Fas MAb
(Westendorf et al, 1995). In some cell lines, the degree of resis-
tance to Fas-mediated apoptosis appears to be directly correlated
with the level ofresistance to chemotherapeutic drugs (Landowski
et al, 1997). The circumstances in which NHLs can resist Fas-
mediated apoptosis are not fully clarified in the literature. Fas
resistance was reported to occur in lymphoma cell lines, and to be
modified by CD40 ligation (Schattner et al, 1996). Like Fas, CD40
belongs to the TNFR superfamily, and regulates B-cell activation
and differentiation (Banchereau et al, 1994; Castigli et al, 1996).
CD40 can induce Fas up regulation on the surface of B cells
(Schattner et al, 1995).
Understanding the regulation of Fas-mediated apoptosis there-
fore appears critical for the development of new therapies against
NHLs. In this report we tried to characterize the susceptibility of
NHL cells to Fas-induced killing and its possible modulation. We
show that Fas resistance frequently occurs in a wide range of
B-NHL subtypes, and that CD40 ligation results in a moderate
increase in the sensitivity to Fas-mediated cell death.
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Table 1 Correlations between Fas-mediated apoptosis and Fas expression in fresh lymphoma cells
Type/casea Control 24 hb Anti-Fas 24 hb Control 48 hb Anti-Fas 48 hb Control 72 hb Anti-Fas 72 hb Constitutive Fas expressionc
1. (FL)
2. (FL)
3. (FL)
4. (FL)
5. (FL)
6. (FL)
7. (FL)
8. (DLCL)
9. (DLCL)
10. (DLCL)
11. (DLCL)
12. (SLL)
13. (SLL)
14. (MCL)
15. (MCL)
16. (MCL)
17. (PTL)
18. (PTL)
3
11
3
6
7
11
2
13
14
18
19
1
17
4
7
5
30
1
9
15
4
7
20
16
9
11
17
11
22
2
20
6
8
4
65
3
7
6
4
2
4
13
3
19
12
21
26
1
12
2
6
11
34
9
10
5
5
2
15
17
5
26
15
22
31
3
14
3
8
23
87
14
12
9
12
8
6
15
2
34
11
12
27
2
12
4
3
21
38
12
36
12
14
10
6
17
4
45
14
21
55
5
15
9
5
26
92
7
34
55
43
56
73
61
66
42
53
68
81
6
2
1
12
13
72
93
aFL, follicular B-cell lymphoma; DLCL, diffuse large B-cell lymphoma; SLL, small lymphocytic lymphoma; MCL, mantle cell lymphoma; PTL, peripheral T-cell
lymphoma. bRefers to the percentage of apoptotic cells. cRefers to the percentage of Fas-positive lymphoma cells.
MATERIAL AND METHODS
Tissue sampling and study design
A series of 18 specimens representative of various subtypes of
human NHLs was analysed. Tumours were obtained from different,
untreated patients. The distribution of cases according to the
Revised European-American Classification of lymphoid
neoplasms (Lee Harris et al, 1994) is detailed in Table 1. A portion
of each sample was submitted to conventional histopathological
processing, standard immunophenotyping and cytogenetic
analysis; fresh lymphoma cells obtained from the rest ofthe sample
were used for flow cytometry (FC) analysis of Fas expression and
for the evaluation of sensitivity to Fas-mediated apoptosis. In addi-
tion, 5 out of these 18 NHLs were submitted to CD40 induction. A
control sample of benign reactive tonsil was analysed in parallel.
Purification and culture of B and T cells from fresh
lymphoma tissues
Surgically removed lymph nodes were immediately processed;
fresh lymphoma cells were obtained by teasing, washed, and resus-
pended in RPMI medium containing 20% fetal calf serum (FCS). B
cells and T cells were separated using magnetic beads conjugated
with anti-CD19 and anti-CD2 mouse IgG MAbs (Immunotech SA,
Marseilles, France). Purified populations were analysed for Fas
expression, and then submitted to Fas-triggering using anti-Fas
MAb with or without CD40 induction. Isolated B cells were
uniformly > 90% CD20+ and < 10% CD3+. Isolated T cells were
> 90% CD3+ and <10% CDl9+. The monoclonality of isolated
malignant B-cell populations was checked by the exclusive detec-
tion of K or ylight chains (Dakopatts, Denmark). Sensitivity ofpuri-
fied cells to Fas-mediated apoptosis was determined as described
below. Culture of B cells using the CD40 system was performed as
described previously (Garrone et al, 1995; Shultze et al, 1995).
Briefly, NIH3T3 cells stably expressing the human CD40 ligand
(CD40L) (a kind gift from Dr Jacques Banchereau, Schering-
Plough, Dardilly, France) were seeded at 1 x 101 cells ml as a
feeder layer before adding the malignant lymphoma cells or normal
tonsil B cells. After 3 days' growth in the presence ofCD40L alone,
anti-Fas MAb was added so that B cells were submitted to both
CD40 and Fas stimulation for 48 to 72 h.
FC analysis
For analysis of Fas expression, lymphoma cells were incubated
with a FITC-conjugated non-apoptosis-inducing anti-Fas MAb
(Clone UB2, Immunotech) for 30 min at 4°C. Cells were then
washed in phosphate-buffered saline (PBS), fixed with 1%
paraformaldehyde and analysed on a FACScan flow cytometer
(Becton Dickinson). Positive controls for Fas expression were
Jurkat cells.
The immunophenotype offresh lymphoma cells was determined
using a panel of conjugated MAbs (Immunotech and Dakopatts)
directed against differentiation antigens specific for B cells (CDI0,
CD19, CD20, CD21, CD22, CD23, CD24, K and y immunoglob-
ulin light chains, 6, ,u, y, and ox immunoglobulin heavy chains), T
cells (CD2, CD3, CD4, CD5, CD7, CD8). For double-colour FC
analysis, cells were labelled with fluorescently (FITC and PE)
tagged MAbs recognizing the cell-surface molecules, Fas, CD3 and
CD19 for 30 min at4°C. They were then washed and fixed with 1%
paraformaldehyde in PBS before analysis.
Assessment of Fas-mediated apoptosis
Sensitivity of lymphoma cells to Fas-mediated apoptosis was
determined in the 18 NHL cases by treatment with the agonistic
anti-Fas 7C 1 1 gM MAb (Immunotech). Purified cell populations
were immediately resuspended in RPMI medium containing 20%
FCS, then incubated with 7C II MAb (1 ,ug x 10-6 cells) for 24-
72 h. The percentages of apoptotic cells were measured by FC
using the anti-7A6 MAb called APO.2.7 (Immunotech) on perme-
abilized cells as described recently (Zhang et al, 1996). Cellular
debris identified on scattergrams and stained by propidium iodide
was gated out before quantification, which was performed in a
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Table 2 Effect of CD40 activation on Fas expression and Fas-induced apoptosis in B-cell NHLs
Cases/typea Induced Fas expressionc Spontaneous apoptosisb Fas-induced apoptosisb
(CD40L, 72 h) (CD40L, day 5-6) (anti-Fas + CD40L, day 5-6)
1 (FL) 97 15 34
8 (DLCL) 89 14 59
13(SLL) 36 13 19
14 (MZL) 47 13 37
15 (MZL) 51 2 24
Normal tonsil B cells 62 6 77
Footnotes as in Table 1.
gate determined after staining with an isotypic control antibody
(Immunotech). Cells displaying non-specific reactivity were
excluded, and the resulting gate was used for apoptosis quantifica-
tion using APO.2.7 staining.
The efficiencies ofapoptotic induction by 7CI I and ofimmuno-
detection using APO.2.7 were controlled on Fas-expressing Jurkat
cells in all the experiments. In one case the sensitivity to apoptosis
of lymphoma B cells was compared with that of the reactive T
cells isolated from the corresponding lymphoma tissue.
Detection of apoptotic cells using the anti-7A6 MAb APO2.7
was compared with detection using annexin staining (Annexin kit,
Immunotech) in Jurkat cells. The results of both methods were
found to be consistent (data not shown). Negative controls were
performed by detection of 7A6 on cell populations incubated with
an isotype-matched antibody.
RESULTS
FC analysis detects weak to moderate levels of Fas
expression on lymphoma cells
The proportion of Fas-positive lymphoma cells was highly vari-
able (mean value 46%) among the 18 lymphoma cases analysed, as
detailed in Table 1. The highest percentage (93%) of Fas expres-
sion was detected in a peripheral T-cell NHL (PTL, case 18), The
lowest percentages (less than 5%) were observed in one small
lymphocytic NHL (SLL, case 13) and one mantle cell NHL (MCL,
case 14). The percentages of Fas-expressing cells detected by
dual-colour FC analysis in total lymphoma cell populations and by
single-colour labeling in purified B- or T-cell subpopulations were
in accordance (data not shown). Control Jurkat cells were nearly
100% Fas positive.
Fresh lymphoma cells display null or weak sensitivity
to Fas-mediated apoptosis
Apoptosis was evaluated by immunodetection of the 7A6 antigen,
which defines an epitope on the mitochondrial membrane that
becomes exposed on cells undergoing apoptosis (Zhang et al,
1996). A strict correlation between anti-7A6 positivity on perme-
abilized cells and levels of apoptosis was reported in peripheral
blood lymphocytes and in lymphoid cell lines (Zhang et al, 1996).
In the case of fresh neoplastic B cells, the spontaneous rate of
apoptosis after 72 h of culture was significantly higher in B-cell
NHLs belonging to the diffuse large-cell subtype (DLCL; mean
value 21%) than in other B-cell NHLs [mean value 9% for follic-
ular NHL (FL) and MCL subtypes, and 7% for SLL].
The difference between the percentages of apoptotic cells in the
presence of anti-Fas mAb 7C11 and of a control MAb gives a
measure ofthe relative sensitivity ofneoplastic B cells to Fas-medi-
ated cell death. This difference was not significant among the 18
NHL cases analysed at any time point (P > 0.1 using the Student's
t-test). Higher concentrations of 7C11 and/or longer incubation
periods had no effect on apoptotic rates (Table 1). No significant
difference was observed among the group of 16 B-cell NHLs
(P > 0.1), although three samples (cases 1, 8 and 11) showed an
increase in the rates ofcell death ranging from 11 % to 28% at 72 h
(Table 1). Again, no significant difference in sensitivity was found
between the different B-cell NHL subtypes (P > 0.1 for all compar-
isons). This difference was slightly more pronounced between
T-cell NHLs and some B-cell subtypes such as FL and MCL (0.1 >
P > 0.05). Similar values were obtained with the control MAb and
with medium alone. No correlation could be observed between the
levels of Fas expression and the sensitivity to Fas killing in the 18
NHL cases tested (P = 0.412 using the Student's correlation test).
We were able to analyse two cases of T-cell NHL, and they
showed very different susceptibilities to 7C11-induced apoptosis.
In one case, malignant T cells were almost as sensitive as control
Jurkat cells, whereas in the second one they appeared as resistant
as neoplastic B cells to 7C11-induced apoptosis.
CD40 ligation on neoplastic B cells induces CD95
up-regulation and a weak to moderate increase in
Fas-induced cell death
As indicated in Table 2, activation of B cells by CD40 ligand
resulted in variable increases in Fas expression in the five B-NHL
cases analysed (Figure IA and B); the final percentages of Fas-
positive cells were roughly correlated with the basal levels of Fas
expression. A similar increase in Fas expression was observed in
normal tonsil B cells upon CD40 ligation (Figure 2). A 3-day incu-
bation with 7Cl1 MAb significantly increased the rates of apo-
ptosis in CD40-activated neoplastic B cells when compared with
incubation with a control MAb (P = 0.008 using the non para-
metric Mann-Whitney test). CD40 ligation was less efficient in the
SLL sample than in the other NHLs tested (Table 2 and Figure 1A
and B). Fas-induced apoptosis appeared higher in tumours
displaying high Fas expression after activation. The overall
increase in apoptotic rates following CD40 activation remained
much lower in tumour samples (mean 23% and maximum 45§o)
than in normal tonsil B cells under the same conditions (71%).
Normal B cells showed a low sensitivity to Fas at onset of the
culture, but became highly sensitive after CD40 ligation and
subsequent Fas up-regulation (Table 2 and Figure 2).
British Journal ofCancer (1998) 78(2), 225-232 0 Cancer Research Campaign 1998228 L Xerri et al
A
FAS APO. 2
No anti-FAS I Anti-FAS
o o
o
0
0
I
a; 111 I".
10° 104 1i0 104
FL -Height FL -Height
c,J
C)
~ ~ ~ 10 io0 0
-Height FLi -Height
C,)
c
0
FL1-Height FLi -Height
0
FL1-Height FLi -Height
0
CMJ
0
H° 104
FL2-Height
FL2-Height
0
0 No 14
g
FL2-Height
FL2-Height
No CD40L
CD40L
0
0
CMJ
0
0
ei7
10° FL2-Height 104 10° FL2-Height 104
No CD40L
CD40L
FL2-Height
British Journal of Cancer (1998) 78(2), 225-232
Neg UB2
0 Cancer Research Campaign 1998Fas-mediated apoptosis in human lymphomas 229
LIFAS
UB2 No anti-FAS Anti-FAS
0
LO 0
0
10° 101 102 i03 104 100 101 102 i03 io4
FL -Height FL -Height
o 0
LO LO
C\Jl 4
A, O||s........
1 0 101 102 103 1 4 1i0 101 102 103 104
FL -Height FL -Height
o 0 c\I 2 0o
oj410 oW;~~~\j
100 101 102i 13 1 10° 10
FL2-Height FL2-Height
0
'°MX~ ~~~~ ^3 CMw 37
1 0 101 102 i03 i04 i 0 101 102 103 104
FL2-Height FL2-Height
I1
Diffuse large-cell lymphoma
FL1 -Height
0
LO
C LO
o~J 89
0
0
-Height
1 i00 FLi-Height 0
0
_~~~~~~
100 i04
FL2-Height FL2-Height
o 0
14
i0° 101 102 i03 i04 100 101 102 103 1(
FL2-Height FL2-Height
I
Figure 1 Effect of CD40 activation on Fas expression and Fas-induced apoptosis in B-cell NHLs (A, cases 13 and 1; B, cases 14 and 8). Surface expression
of Fas was detected by single-colour flow cytometry using the UB2 MAb (UB2) or an isotype matched antibody as a negative control (NEG). Fas detection was
performed on untreated fresh lymphoma cells (no CD40L) and after 72 h culture on a monolayer of CD40L-transfected cells (CD40L). Fas-induced apoptosis
was evaluated by flow cytometry using the APO.2.7 MAb (APO.2) after incubation with the apoptotic inducer anti-Fas mAb 7C11 (anti-Fas) or a control MAb (no
anti-Fas), with (CD40) or without (no CD40L) simultaneous CD40 stimulation. Significant increase in Fas expression and Fas-induced cell death were observed
following CD40 stimulation. Percentages of positive cells are indicated in each histogram, except in the NEG column, in which virtually 100% of cells were
negative
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Figure 2 Comparison of Fas-induced apoptosis in normal tonsil B cells, control Jurkat cells, fresh lymphoma cells and reactive T cells isolated from the same
MCL biopsy sample (case 15). Histograms show the detection of apoptotic cells by flow cytometry using the APO.2.7 MAb, following a 48 h incubation with
either the 7C11 MAb (anti-Fas) or a control MAb (no anti-Fas). CD40 activation was applied to normal and neoplastic B cells as indicated in the legend to Figure
1. The levels of Fas expression in the different test conditions are indicated above the histograms.
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DISCUSSION
The Fas receptor present on the surface of normal activated
lymphocytes can trigger their death upon appropriate stimulation
(Garrone et al, 1995). CD40 is a membrane molecule expressed on
both normal and malignant B cells (Banchereau et al, 1994).
Binding of its ligand (CD40L) transduces activation and survival
signals, and can lead to an increase in Fas expression (Banchereau
et al, 1994; Schattner et al, 1995; Castigli et al, 1996). Normal B
cells were reported to be initially resistant to killing via the Fas
pathway, and to become sensitive upon CD40 activation, which
results in a gradual increase in Fas expression (Garrone et al, 1995;
Choe et al, 1996). We also observed that resting B cells express low
Fas levels, but are efficiently induced to express a functional Fas
molecule after CD40 ligation. The present report shows in addition
that constitutive resistance to Fas-mediated apoptosis is observed in
most B-cell NHLs, that it is not associated with a specific histo-
logical subtype and not correlated with Fas expression levels.
Although a significant up-regulation of Fas expression was
observed upon CD40 ligation, Fas-mediated cell death was only
partially restored in these cases. The levels of cell death in NHLs
were never comparable to those observed for CD40-activated tonsil
B cells or control Jurkat cells. Although the number of lymphoma
cases is relatively small to enable a final conclusion to be drawn,
these differences in the behaviour of malignant B cells and normal
tonsil B cells suggest that NHLs may harbour defects either in the
Fas receptor itself or in the downstream apoptotic pathway.
If one considers the hypothesis of a defect in the downstream
pathway, the potential implication of Bcl-2 should be considered,
as it can protect cells from apoptosis induced by a number of
stimuli, including Fas triggering, in some experimental systems
(Itoh et al, 1993). We analysed Bcl-2 expression using reverse
transcriptase-polymerase chain reaction (RT-PCR) in the 18 NHL
cases, and found no correlation between the level of expression
and the sensitivity to Fas killing (data not shown). These results do
not exclude a possible role of other members of the Bcl-2 family,
such as Bcl-xL, which was demonstrated to decrease Fas killing
when transfected into apoptosis-sensitive myeloma cells (Gauthier
et al, 1996); we reported previously that the majority of human
NHLs express substantial amounts of Bcl-xL (Xerri et al, 1996).
The defect could be linked alternatively to the effectors of apop-
tosis including caspases, which are known to control the distal
point of a common apoptotic pathway shared by many cell death
inductors (Casciola-Rosen et al, 1996; Henkart, 1996). Among
caspases, CPP32 seems to play a particular role in the lymphoid
system, as it is expressed, as an inactive precursor (pro-CPP32), in
germinal centres and in some NHLs (Krajewski et al, 1997; Xerri
et al, 1997). Dysfunction in the CPP32 activating pathway thus
cannot be ruled out. Further investigations are required to unravel
the respective roles played by the ever increasing number of
molecules involved in apoptosis.
One can also speculate that the primary structure of Fas is
altered in lymphoma cells, thus rendering the molecule inactive.
Structural defects have been identified in some Fas-resistant cell
lines that harbour a truncated Fas molecule (Cascino et al, 1996).
Our previous search for rearrangements and/or deletions ofthe Fas
gene in a large series ofhuman lymphoma samples did not reveal a
frequent occurrence of such abnormalities (Xerri et al, 1995b),
although the presence ofpoint mutations cannot be ruled out.
Our results on NHLs slightly differ from those of Schattner
et al (1996), who recently reported that four out of six Burkitt's
lymphoma (BL) cell lines and one fresh BL sample manipulated
by T cells expressing CD40L were rendered highly susceptible to
Fas-mediated cytolysis. Nonetheless, it is possible that the suscep-
tibility to Fas-induced apoptosis of BL cells differs from that of
other B-cell NHLs, as BL appears to be antigen driven (Jain et al,
1994), and as engagement of the antigen receptor interferes with
apoptosis on B-cells (Choe et al, 1996). Another possibility is that
cytokines produced by T cells are required to prime neoplastic B
cells optimally for Fas-induced apoptosis.
Wang et al (1997) reported a moderate increase in Fas-induced
cell death after CD40 activation in nine out of ten NHLs; the
apoptotic rates reported in the later study were higher than in the
present one. This difference may be due to the addition of inter-
leukin 4 (IL-4) during CD40 stimulation. However, our findings
are in close agreement with a more recent report (Plumas et al,
1998) in which the addition of IL-4 during CD40 stimulation was
shown to have no significant influence on Fas-induced lymphoma
cell death.
Finally, this report establishes that resistance to Fas-induced
apoptosis is a widespread phenomenon in B-cell NHLs, irrespec-
tive of their histological subtype, whereas susceptibility of T-cell
NHLs appears more heterogeneous and needs to be further investi-
gated. In addition, CD40 activation of human malignant B cells
seems not able to circumvent completely the resistance to Fas
killing; Fas-based therapies may only be applicable to a restricted
number of NHLs. The mechanisms underlying the resistance of
NHL cells to apoptosis must be further clarified before a thera-
peutic strategy can be elaborated.
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